# US 2001/0024650 A1 · Artery - and vein-specific proteins and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024650 A1
- Document ID: US20010024650A1
- Status: Published application
- Kind: A1
- Application number: 09/823,009
- Filed: 2001-03-30
- Published: 2001-09-27
- Earliest claimed: 1998-04-13
- Assignees: California Institute of Technology
- Inventors: Hai U. Wang; Zhoufeng Chen; David J. Anderson
- Web page: https://patentgrep.com/patent/US20010024650A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 67/0276: Knock-out vertebrates
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 5/0691: {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0375: Animal model for cardiovascular diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2503/02: Drug screening
- G01N 2333/52: Assays involving cytokines
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.

## Claims

### Claim 1

A method for altering angiogenesis in a mammal, comprising administering to the mammal, in a therapeutically effective quantity, a drug which alters binding or interaction of an artery-specific cell surface molecule with a vein-specific cell surface molecule in a therapeutically effective quantity.

### Claim 2 (depends on 1)

The method of claim 1 wherein the artery-specific cell surface molecule is an artery-specific ligand or receptor and the vein-specific cell surface molecule is a vein-specific receptor or ligand.

### Claim 3 (depends on 1)

The method of claim 1 wherein the artery-specific cell surface molecule is an Ephrin family ligand and the vein-specific cell surface molecule is an Eph family receptor.

### Claim 4 (depends on 3)

The method of claim 3 wherein angiogenesis is inhibited and the drug interferes with binding or interaction of the artery-specific Ephrin family ligand with the vein-specific Eph family receptor.

### Claim 5 (depends on 3)

The method of claim 3 wherein angiogenesis is enhanced and the drug enhances binding or interaction of the artery-specific Ephrin family ligand with its vein-specific Eph family receptor.

### Claim 6 (depends on 3)

The method of claim 3 wherein the drug is an antagonist of the artery-specific Ephrin family ligand or an antagonist of the vein-specific Eph family receptor.

### Claim 7 (depends on 3)

The method of claim 3 wherein the artery-specific Ephrin family ligand is EphrinB2 and the vein-specific Eph family receptor is EphB4.

### Claim 8

A method for selectively delivering a drug to arteries in a mammal, comprising administering to the mammal a complex comprising:
a) the drug and
b) a component which binds an artery-specific cell surface molecule, under conditions appropriate for the component of (b) to bind the artery-specific cell surface molecule, whereby the drug is delivered to arteries.

### Claim 9 (depends on 8)

The method of claim 8, wherein the artery-specific cell surface molecule is a ligand or receptor.

### Claim 10 (depends on 8)

The method of claim 8, wherein the artery-specific cell surface molecule is an Ephrin family ligand.

### Claim 11 (depends on 1)

The method of claim 1 0 wherein the drug is an anti-angiogenic drug and the component of (b) is an antibody specific for the artery-specific Ephrin family ligand, or a receptor of the artery-specific Ephrin family ligand.

### Claim 12 (depends on 10)

The method of claim 10 wherein the artery-specific Ephrin family ligand is EphrinB2.

### Claim 13 (depends on 12)

The method of claim 12 wherein the drug is an anti-angiogenic drug.

### Claim 14 (depends on 12)

The method of claim 12 wherein the drug is an angiogenic drug.

### Claim 15

A method for selectively delivering a drug to veins in a mammal, comprising administering to the mammal a complex comprising:
a) the drug, and
b) a component which binds a vein-specific cell surface molecule, under conditions appropriate for the component of (b) to bind the vein-specific cell surface molecule, whereby the drug is delivered to veins.

### Claim 16 (depends on 15)

The method of claim 15 wherein the vein-specific cell surface molecule is a receptor or ligand.

### Claim 17 (depends on 15)

The method of claim 15, wherein the vein-specific cell surface molecule is a vein-specific Eph family receptor.

### Claim 18 (depends on 17)

The method of claim 17 wherein the drug is an anti-angiogenic drug and the component of (b) is an antibody specific for the vein-specific Eph family receptor, or a ligand of the vein-specific Eph family receptor.

### Claim 19 (depends on 17)

The method of claim 17 wherein the vein-specific Eph family receptor is EphB4.

### Claim 20 (depends on 19)

The method of claim 19 wherein the drug is an anti-angiogenic drug.

### Claim 21 (depends on 19)

The method of claim 19 wherein the drug is an angiogenic drug.

### Claim 22

A transgenic mouse having an indicator gene which is detectably expressed in cells of arteries but not cells of veins.

### Claim 23 (depends on 22)

The mouse of claim 22 wherein the indicator gene is inserted in an artery-specific Ephrin family ligand gene.

### Claim 24

A transgenic mouse of genotype EphrinB2+−.

### Claim 25

A transgenic mouse in which EphrinB2 genes comprise an insertion that marks all arteries but not veins.

### Claim 26

A transgenic mouse of genotype EphrinB2taulacZ/+.

### Claim 27

A method for identifying artery cells in a mouse having an indicator gene inserted in one or more alleles of EphrinB2, comprising staining a section of the mouse with a substance appropriate for detection of expression of the indicator gene.

### Claim 28

A transgenic mouse having an indicator gene which is expressed in venous endothelial cells but not in arterial endothelial cells.

### Claim 29 (depends on 28)

The mouse of claim 28 wherein the indicator gene is inserted in a vein-specific Eph family receptor gene.

### Claim 30 (depends on 29)

The transgenic mouse of claim 29 wherein the vein-specific Eph family receptor gene encodes EphB4.

### Claim 31

A transgenic mouse of genotype EphB4+/−.

### Claim 32

A method for identifying vein cells in a mouse having an indicator gene inserted in one or more alleles of EphB4, comprising staining a section of the mouse with a substance appropriate for detection of expression of the indicator gene.

### Claim 33

A method for testing an effect of a drug on growth of arteries, comprising administering the drug to a mouse having an indicator gene inserted in a gene specifically expressed in arteries, observing the effect of the drug, and comparing the effect to that produced in a suitable control mouse.

### Claim 34

A method for testing an effect of a drug on growth of veins, comprising administering the drug to a mouse having an indicator gene inserted in a gene specifically expressed in veins, observing the effect of the drug, and comparing the effect to that produced in a suitable control mouse.

### Claim 35

A method for identifying arterial endothelial cells in a tissue sample, comprising contacting the tissue sample with a molecule which binds to EphrinB2, wherein said molecule is linked to a label, and detecting the label, wherein if label is detected on a cell, the cell is an arterial endothelial cell.

### Claim 36 (depends on 35)

The method of claim 35, wherein said molecule is an antibody.

### Claim 37

A method for identifying venous endothelial cells in a tissue sample, comprising contacting the tissue sample with a molecule which binds to EphB4, wherein said molecule is linked to a label, and detecting the label, wherein if label is detected on a cell, the cell is a venous endothelial cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein said molecule is an antibody.

### Claim 39

A method for directing a substance to arteries in a mammal, comprising administering to the mammal a complex which comprises the substance linked to a moiety which binds EphrinB2.

### Claim 40

A method for directing a substance to veins in a mammal, comprising administering to the mammal a complex which comprises the substance linked to a moiety which binds EphB4.

### Claim 41

A method for altering development of blood vessels in a mammal, comprising administering to the mammal a soluble polypeptide comprising the extracellular domain of an artery-specific cell surface protein or a soluble polypeptide comprising the extracellular domain of a vein-specific cell surface protein.

### Claim 42 (depends on 41)

The method of claim 41 wherein the artery-specific cell surface protein is an Ephrin family ligand and the vein-specific cell surface protein is an Eph family receptor.

### Claim 43 (depends on 42)

The method of claim 42 wherein the Ephrin family ligand is EphrinB2 and the Eph family receptor is EphB4.

### Claim 44

A method for identifying a drug that inhibits interaction of an arterial endothelial cell-specific surface molecule with a venous endothelial cell-specific surface molecule, comprising:
a) combining:
1) the arterial endothelial cell-specific surface molecule;
2) the venous endothelial cell-specific surface molecule; and
3) a drug to be assessed for its ability to inhibit interaction between the molecule of (1) and the molecule of (2), under conditions appropriate for interaction between the molecule of (1) and the molecule of (2);
b) determining the extent to which the molecule of (1) and the molecule of (2) interact; and
c) comparing the extent determined in (b) with the extent to which interaction of the molecule of (1) and the molecule of (2) occurs in the absence of the drug to be assessed and under the same conditions appropriate for interaction of the molecule of (1) with the molecule of (2);
wherein if the extent to which interaction of the molecule of (1) and the molecule of (2) is less in the presence of the drug than in the absence of the drug, the drug is one which inhibits interaction of the arterial endothelial cell-specific molecule of (1) with the venous endothelial cell-specific molecule of (2).

### Claim 45 (depends on 44)

The method of claim 44 wherein the arterial endothelial cell-specific surface molecule is an Ephrin family ligand and the venous endothelial cell-specific surface molecule is an Eph family receptor.

### Claim 46 (depends on 45)

The method of claim 45 wherein the Ephrin family ligand is EphrinB2 and the Eph family receptor is EphB4.

### Claim 47

A method for identifying a drug that enhances interaction of an arterial endothelial cell-specific surface molecule with a venous endothelial cell-specific surface molecule, comprising:
a) combining:
1) the arterial endothelial cell-specific surface molecule;
2) the venous endothelial cell-specific surface molecule; and
3) a drug to be assessed for its ability to inhibit interaction between the molecule of (1) and the molecule of (2), under conditions appropriate for interaction between the molecule of (1) and the molecule of (2);
b) determining the extent to which the molecule of (1) and the molecule of (2) interact; and
c) comparing the extent determined in (b) with the extent to which interaction of the molecule of (1) and the molecule of (2) occurs in the absence of the drug to be assessed and under the same conditions appropriate for interaction of the molecule of (1) with the molecule of (2);
wherein if the extent to which interaction of the molecule of (1) and the molecule of (2) is greater in the presence of the drug than in the absence of the drug, the drug is one which enhances interaction of the arterial endothelial cell-specific molecule of (1) with the venous endothelial cell-specific molecule of (2).

### Claim 48 (depends on 47)

The method of claim 47 wherein the arterial endothelial cell-specific surface molecule is an Ephrin family ligand and the venous endothelial cell-specific surface molecule is an Eph family receptor.

### Claim 49 (depends on 48)

The method of claim 48 wherein the Ephrin family ligand is EphrinB2 and the Eph family receptor is EphB4.

### Claim 50

A method for isolating arterial endothelial cells, comprising dissociating cells of a tissue sample comprising arterial endothelial cells, contacting the dissociated cells with a substance which binds to a cell-surface protein expressed specifically on arterial endothelial cells, and separating the cells which have bound the substance from the cells which have not bound the substance.

### Claim 51

A method for isolating arterial endothelial cells, comprising dissociating cells of a tissue sample comprising arterial endothelial cells, contacting the cells with a substance which binds to a cell-surface protein expressed specifically on arterial endothelial cells, wherein said substance is bound to a solid support, removing cells which do not bind to the substance, and releasing the arterial endothelial cells from the solid support.

### Claim 52

A method for isolating venous endothelial cells, comprising dissociating cells of a tissue sample comprising venous endothelial cells, contacting the dissociated cells with a substance which binds to a cell-surface protein expressed specifically on venous endothelial cells, and separating the cells which have bound the substance from cells which have not bound the substance.

### Claim 53

A method for isolating venous endothelial cells, comprising dissociating cells of a tissue sample comprising venous endothelial cells, contacting the cells of the tissue sample with a substance which binds to a cell-surface protein expressed specifically on venous endothelial cells, wherein said substance is bound to a solid support, removing cells which do not bind to the substance, and releasing the venous endothelial cells from the solid support.

### Claim 54

Isolated arterial endothelial cells.

### Claim 55

Isolated venous endothelial cells.

### Claim 56

A method for assessing an effect of one or more drugs on arteries, comprising adding one or more drugs to isolated arterial endothelial cells, and observing the cells for the effect.

### Claim 57

A method for assessing an effect of one or more drugs on veins, comprising adding one or more drugs to isolated venous endothelial cells, and observing the cells for the effect.

### Claim 58

A cell line derived from arterial endothelial cells.

### Claim 59

A cell line derived from venous endothelial cells.

### Claim 60

A cell line which produces a protein that is detectably produced in arteries, but is not detectably produced in veins.

### Claim 61

A cell line which produces a protein that is detectably produced in veins, but is not detectably produced in arteries.

### Claim 62

A cDNA library produced from isolated arterial endothelial cells.

### Claim 63

A cDNA library produced from isolated venous endothelial cells.

### Claim 64

A method for identifying a gene which shows differential expression in venous endothelial cells compared to arterial endothelial cells, comprising producing a transgenic mouse having an indicator insertion gene in a gene to be tested for differential expression, and observing expression of the indicator insertion gene, wherein a difference in expression of the indicator insertion gene in venous endothelial cells and arterial endothelial cells indicates a gene which shows differential expression.

### Claim 65

A method for modifying arteries in a mammal, comprising genetically altering isolated arterial endothelial cells and introducing the altered cells into the mammal.

### Claim 66

A method for modifying veins in a mammal, comprising genetically altering isolated veins endothelial cells and introducing the altered cells into the mammal.

### Claim 67

A method for identifying differentially expressed genes comprising;
a) dissociating cells of a tissue sample comprising arterial endothelial cells;
b) contacting the dissociated cells with a first substance which binds to a cell-surface protein expressed specifically on arterial endothelial cells;
c) separating the arterial endothelial cells which have bound said first substance from the cells which have not bound said first substance where the bound cells are arterial endothelial cells;
d) dissociating cells of a tissue sample comprising venous endothelial cells;
e) contacting the dissociated cells with a second substance which binds to a cell-surface protein expressed specifically on venous endothelial cells;
f) separating the cells which have bound said second substance from cells which have not bound said second substance wherein cells which have bound are venous endothelial cells;
g) subjecting the separated arterial endothelial cells from step (c) and the venous endothelial cells from step (f) to conditions for differential expression; and
h) identifying differentially expressed genes.

### Claim 68 (depends on 67)

A gene identified by the method of claim 67.

### Claim 69 (depends on 68)

The gene of claim 68 being expressed by an arterial endothelial cell but not a venous endothelial cell.

### Claim 70 (depends on 68)

The gene of claim 68 being expressed by a venous endothelial cell but not an arterial endothelial cell.

### Claim 71 (depends on 67)

A method of identifying a gene product expressed by a gene of claim 67 in arterial endothelial cells comprising isolating said gene product from an arterial endothelial cDNA library.

### Claim 72 (depends on 67)

A method of identifying a gene product expressed by a gene of claim 67 in venous endothelial cells comprising isolating said gene product from a venous endothelial cDNA library.

### Claim 73 (depends on 71)

A molecule which binds to the gene product of claim 71.

### Claim 74 (depends on 72)

A molecule which binds to the gene product of claim 72.

### Claim 75 (depends on 73)

The molecule of claim 73 wherein said molecule is an antibody.

### Claim 76 (depends on 73)

The molecule of claim 73 wherein said molecule is a protein or a fragment thereof.

### Claim 77 (depends on 73)

The molecule of claim 73 wherein said molecule is a small molecule.

### Claim 78 (depends on 74)

The molecule of claim 74 wherein said molecule is an antibody.

### Claim 79 (depends on 74)

The molecule of claim 74 wherein said molecule is a protein or a fragment thereof.

### Claim 80 (depends on 74)

The molecule of claim 74 wherein said molecule is a small molecule.

### Claim 81

A method for identifying differentially expressed genes comprising:
a) dissociating cells of a tissue sample comprising arterial endothelial cells;
b) contacting the cells with a first substance which binds to a cell-surface protein expressed specifically on arterial endothelial cells, wherein said first substance is bound to a first solid support;
c) removing cells which do not bind to said first substance;
d) releasing the arterial endothelial cells from said first solid support;
e) dissociating cells of a tissue sample comprising venous endothelial cells;
f) contacting the cells of the tissue sample with a second substance which binds to a cell-surface protein expressed specifically on venous endothelial cells, wherein said second substance is bound to a second solid support;
g) removing cells which do not bind to said second substance;
h) releasing the venous endothelial cells from said second solid support;
i) subjecting the released arterial endothelial cells and the venous endothelial cells in steps (d) and (h) to conditions for differential expression; and
j) identifying differentially expressed genes.

### Claim 82 (depends on 67)

The arterial endothelial cells separated by the method of claim 67.

### Claim 83 (depends on 67)

The venous endothelial cells separated by the method of claim 67.

### Claim 84 (depends on 81)

The arterial endothelial cells released by the method of claim 81.

### Claim 85 (depends on 81)

The venous endothelial cells released by the method of claim 81.

### Claim 86 (depends on 82)

A cell line derived from the arterial endothelial cells of claim 82.

### Claim 87 (depends on 83)

A cell line derived from the venous endothelial cells of claim 83.

### Claim 88 (depends on 84)

A cell line derived from the arterial endothelial cells of claim 84.

### Claim 89 (depends on 85)

A cell line derived from the venous endothelial cells of claim 85.

### Claim 90 (depends on 86)

The cell line of claim 86 which produces a protein that is detectably produced in arteries, but not detectably produced in veins.

### Claim 91 (depends on 87)

The cell line of claim 87 which produces a protein that is detectably produced in veins, but not detectably produced in arteries.

### Claim 92 (depends on 88)

The cell line of claim 88 which produces a protein that is detectably produced in arteries, but not detectably produced in veins.

### Claim 93 (depends on 89)

The cell line of claim 89 which produces a protein that is detectably produced in veins, but not detectably produced in arteries.

### Claim 94 (depends on 82)

A method for assessing an effect of one or more drugs on arteries comprising isolating the arterial endothelial cells of claim 82, adding one or more drugs to said cells and observing the cells for effect.

### Claim 95 (depends on 83)

A method for assessing an effect of one or more drugs on veins comprising isolating the venous endothelial cells of claim 83, adding one or more drugs to said cells and observing the cells for effect.

### Claim 96 (depends on 84)

A method for assessing an effect of one or more drugs on arteries comprising isolating the arterial endothelial cells of claim 84, adding one or more drugs to said cells and observing the cells for effect.

### Claim 97 (depends on 85)

A method for assessing an effect of one or more drugs on veins comprising isolating the venous endothelial cells of claim 85, adding one or more drugs to said cells and observing the cells for effect.

### Claim 98

A method for identifying differentially expressed genes comprising;
a) dissociating cells of a tissue sample comprising arterial endothelial cells;
b) contacting the dissociated cells with a first substance which binds to an Ephrin family ligand expressed specifically on arterial endothelial cells;
c) separating the arterial endothelial cells which have bound said first substance from the cells which have not bound said first substance where the bound cells are arterial endothelial cells;
d) dissociating cells of a tissue sample comprising venous endothelial cells;
e) contacting the dissociated cells with a second substance which binds to an Eph family receptor expressed specifically on venous endothelial cells
f) separating the cells which have bound said second substance from cells which have not bound said second substance wherein cells which have bound are venous endothelial cells;
g) subjecting the separated arterial endothelial cells from step (c) and the venous endothelial cells from step (f) to conditions for differential expression; and
h) identifying differentially expressed genes.

### Claim 99

A method for identifying differentially expressed genes comprising;
a) dissociating cells of a tissue sample comprising arterial endothelial cells;
b) contacting the dissociated cells with a first substance which binds to EphrinB2 expressed on arterial endothelial cells;
c) separating the arterial endothelial cells which have bound said first substance from the cells which have not bound said first substance where the bound cells are arterial endothelial cells;
d) dissociating cells of a tissue sample comprising venous endothelial cells;
e) contacting the dissociated cells with a second substance which binds to EphB4 expressed on venous endothelial cells;
f) separating the cells which have bound said second substance from cells which have not bound said second substance wherein cells which have bound are venous endothelial cells;
g) subjecting the separated arterial endothelial cells from step (c) and the venous endothelial cells from step (f) to conditions for differential expression; and
h) identifying differentially expressed genes.

### Claim 100 (depends on 98)

A gene identified by the method of claim 98.

### Claim 101 (depends on 100)

The gene of claim 100 being expressed by an arterial endothelial cell but not a venous endothelial cell.

### Claim 102 (depends on 100)

The gene of claim 100 being expressed by a venous endothelial cell but not an arterial endothelial cell.

### Claim 103 (depends on 98)

The arterial endothelial cells separated by the method of claim 98.

### Claim 104 (depends on 98)

The venous endothelial cells separated by the method of claim 98.

### Claim 105 (depends on 99)

The arterial endothelial cells separated by the method of claim 99.

### Claim 106 (depends on 99)

The venous endothelial cells separated by the method of claim 99.

### Claim 107 (depends on 103)

A cell line derived from the arterial endothelial cells of claim 103.

### Claim 108 (depends on 104)

A cell line derived from the venous endothelial cells of claim 104.
